PURPOSE: The International Berlin-Frankfurt-Münster (BFM) study group conducted a study on pediatric acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD) was assessed using flow cytometry (FCM), and the impact of early intensification and methotrexate (MTX) dose on survival was evaluated. PATIENTS AND METHODS: We included 6,187 patients younger than 19 years. MRD by FCM refined the risk group definition previously used in the ALL intercontinental-BFM 2002 study on the basis of age, WBC count, unfavorable genetic aberrations, and treatment response measured morphologically. Patients at intermediate risk (IR) and high risk (HR) were randomly assigned to protocol augmented protocol I phase B (IB) versus IB regimen. MTX doses of 2 versus 5 g/m2 every 2 weeks, four times, were evaluated in precursor B-cell-ALL (pcB-ALL) IR. RESULTS: The 5-year event-free survival (EFS ± SE) and overall survival (OS ± SE) rates were 75.2% ± 0.6% and 82.6% ± 0.5%, respectively. Their values in risk groups were standard risk (n = 624), 90.7% ± 1.4% and 94.7% ± 1.1%; IR (n = 4,111), 77.9% ± 0.7% and 85.7% ± 0.6%; and HR (n = 1,452), 60.8% ± 1.5% and 68.4% ± 1.4%, respectively. MRD by FCM was available in 82.6% of cases. The 5-year EFS rates in patients randomly assigned to protocol IB (n = 1,669) and augmented IB (n = 1,620) were 73.6% ± 1.2% and 72.8% ± 1.2%, respectively ( P = .55), while those in patients receiving MTX doses of 2 g/m2 (n = 1,056) and MTX 5 g/m2 (n = 1,027) were 78.8% ± 1.4% and 78.9% ± 1.4%, respectively ( P = .84). CONCLUSION: The MRDs were successfully assessed using FCM. An MTX dose of 2 g/m2 was effective in preventing relapse in non-HR pcB-ALL. Augmented IB showed no advantages over the standard IB. [Media: see text]
BK polyomavirus (BKPyV) is a pathogen responsible for infectious complications in hematopoietic stem cell transplant (HSCT) recipients. This review aims to give an insight into recent data about the structure and genomic organization, epidemiology, clinical manifestations, diagnosis, and current treatment options of BKPyV infections in children after HSCT. News regarding viral replication and pathogenesis include the generation of miRNA, new mechanisms of viral shedding by releasing infectious particles via extracellular vesicles, and human bladder microvascular endothelial cells probably acting as viral reservoirs enabling low-level viral replication and persistence. In studies conducted over the past five years, BKPyV hemorrhagic cystitis (BKPyV-HC) has a prevalence rate of 4 to 27% in children undergoing HSCT. Diagnostics still has unsolved dilemmas like whole blood or plasma samples as well as the standardization of molecular methods to allow for reporting in international units. In terms of treatment, new approaches have been used in the past five years, including the use of mesenchymal stem cells (MSCs), virus-specific T cells (VSTs), and recombinant human keratinocyte growth factor (rH-KGF), although the efficacy of some of these treatments has only been documented in isolated studies. This complication continues to pose a substantial clinical challenge, characterized by an absence of effective preventive and therapeutic measures.
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Good overall survival rates of about 90% are the result of improvements in risk stratification and risk-adapted therapy, intensive chemotherapy regimens, hematopoietic stem cell transplantation, and better supportive care. Background and Objectives: The aim of this study is to review the epidemiology, prognostic factors, and causes of death in pediatric ALL patients treated at a tertiary care center, and to identify risk factors influencing clinical outcomes. Materials and Methods: A retrospective study was conducted at the Department of Pediatric Hematology and Oncology, University Hospital Centre Zagreb, including 302 children (0–18 years) diagnosed with ALL between January 2001 and December 2015. Results: Two hundred fifty-one children survived (5-year overall survival 83%). Relapse occurred in 13.6% of patients. Relapse rates were higher for B-cell precursor (Bcp)-ALL than for T-cell ALL (14.3% vs. 10.4%), and no patient with relapsed T-cell ALL survived. The main causes of death were refractory/relapsed disease (43% of patients), followed by infections (35%) and GVHD (8%). The most frequent causes of infectious death were Pseudomonas aeruginosa and Aspergillus fumigatus. The most critical treatment periods were the induction and reinduction phases, especially the de-escalation of corticosteroids. The time of relapse and risk group were independent factors in predicting the outcome. Conclusions: Relapse and infections were the leading causes of death in children with ALL, with the highest mortality observed during induction and reinduction phases. Survival was significantly influenced by relapse timing and risk group, with no survivors among relapsed T-ALL patients.
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Excellent overall survival rate of about 90% are the result of improvements in risk stratification and risk-adapted therapy, intensive chemotherapy regimens, hematopoietic stem cell transplanta-tion and supportive care. Background and Objectives: The aim of this study is to review the epi-demiology, prognostic factors, and causes of death of pediatric ALL in a terciary center. Mate-rials and Methods: A retrospective study was conducted at the Croatian Referral Center for Pe-diatric Hematology and Oncology, University Hospital Centre Zagreb, including 302 children (0–18 years) diagnosed with ALL between January 2001 and December 2015, accounting for about 70% of national cases. Results: Two hundred fifty-one children survived (5-year overall survival 83%). Relapse occurred in 13.6% of patients. Relapse rates were higher for B-cells pre-cursor ALL than for T-cell ALL (14.3% vs. 10.4%), and no patient with relapsed T-cell ALL survived. Main causes of death were refractory/relapsed disease (43% of patients), followed by infections (35%) and GVHD (8%). The most frequent causes of infectious death were Pseudo-monas aeruginosa and Aspergillus fumigatus. The most critical treatment periods were induc-tion and reinduction phases, especially de-escalation of corticosteroids. The time of relapse and risk group were independent factors in predicting the outcome. Conclusions: Our study con-firmed that relapse and infections are major causes of mortality in children with ALL. To im-prove the outcome, we should encourage participation in collaborative international trials, im-provement of supportive care and implementation of new treatment modalities.
Haemophilia is rare, inherited and severe bleeding disorder characterised with factor VIII or factor IX deficiency. The estimated glomerular filtration rate (eGFR) is one of the best-performing methods to evaluate kidney function. Glomerular filtration rate cannot be directly measured; however, it can be determined by measuring the clearance of an ideal filtration marker or estimated using predictive formulas. The aim of this preliminary study was to calculate eGFR of paediatric haemophilia patients treated in our centre and asses the correlation of eGFR calculated by creatinine-based and cystatin C-based equations. In our study, we included 36 boys with moderate or severe haemophilia. Out of a total of 36 patients, 27 had haemophilia A and 9 had haemophilia B. Their mean age was 11.2±4.31 years, with a range from 3 to 18 years. We investigated the correlation and agreement between two eGFR equations (creatinine-based ‘Bedside Schwartz’ equation and cystatin-C based equation). Along with applying correlation and linear regression tests, the Bland Altman test was performed to assess the agreement of the results. Statistically significant differences were found between the mean eGFR values (p<0.001). No significant correlation was found between the two methods (p=0.07). Bland-Altman analysis results showed higher mean eGFR values of bedside Schwartz equation compared to the cystatin-C based formula, meaning that a significant disagreement was found between those two equations. However, within the group of haemophilia B patients, statistically significant positive correlations between the two methods were found, although still a disagreement was observed Due to the observed disagreements between eGFR within haemophilia patients, further research is needed to find the optimal measure of eGFR. We suggest extending this study on a larger cohort of patients and include other possible eGFR equations.
Lymphomas are the third most common malignant disease in childhood, after leukemia and brain tumors. The aim of this study is to show stratification by gender and age as well as long term survival in pediatric patients diagnosed with Non-Hodgkin Lymphoma in our center. Our retrospective analysis included 85 children with newly diagnosed NHL from January 1, 1997 to December 31, 2016. They all have been diagnosed and treated at the Department of Pediatric Hematology and oncology, University Hospital Centre Zagreb. Out of 85 children with newly diagnosed NHL 48 of them suffered from B-cell NHL (n = 48; 56%) while the rest of them had T-cell lymphoblastic lymphoma (T-LBL) (n = 20; 24%) or Anaplastic large-cell lymphoma (ALCL) (n = 17; 20%). There were 25 girls and 50 boys (age 3 – 17 years). Overall survival (OS) for the entire group was 78.82%. Diagnose based survival is in the favor of T-LBL – 85.00% in comparison to 81.25% in B-NHL and 64.71% in ALCL. Our survival rates are not very different from the ones in the other European countries. We expect improved survival rates after introducing novel treatment that would optimize therapeutic effect and at the same time minimize the risk of severe late toxic effects.